(¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°Á : 2024-03-09 |
|
(¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°Á : 2024-03-09 ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°Á ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ ´ã´çÀÚ : ´ëÇѽÅÀåÇÐȸ À̸ÞÀÏ : ksn@ksn.or.kr ±³À°Á¾·ù : ³»°ú Âü¼®¿¹»óÀÎ : 200¸í Áö¿ª : ¼¿ïƯº°½Ã ¼¼ºÎ¼ö°·á : 20,000¿ø ºñ°í Àü¹®ÀÇ, °³¿øÀÇ : 20,000¿ø / ÀüÀÓÀÇ, °£È£»ç, ±âŸ : 10,000¿ø
±³À°½Ã°£ 03¿ù 09ÀÏ ¿Â¶óÀÎ 09:10~09:40 Novel iron therapy in CKD patients with anemia À±ÇØ·æ(¿¬¼¼ÀÇ´ë ½ÅÀå³»°ú) ±³À°½Ã°£ 03¿ù 09ÀÏ ¿Â¶óÀÎ 09:40~10:05 Pros in use of HIF-Prolyl Hydroxylase Inhibition for renal anemia ¾ÈÁ¤³²(ÇѸ²ÀÇ´ë ½ÅÀå³»°ú) ±³À°½Ã°£ 03¿ù 09ÀÏ ¿Â¶óÀÎ 10:05~10:30 Cons in use of HIF-Prolyl Hydroxylase Inhibition for renal anemia °í°Áö(°í·ÁÀÇ´ë ½ÅÀå³»°ú) ±³À°½Ã°£ 03¿ù 09ÀÏ ¿Â¶óÀÎ 10:30~11:10 Reappraisal of transfusion-transmitted infections °í´ëÇö(¿ï»êÀÇ´ë Áø´Ü°Ë»çÀÇÇаú) ±³À°½Ã°£ 03¿ù 09ÀÏ ¿Â¶óÀÎ 11:10~11:40 Recent updates in the diagnosis and treatment of monoclonal gammopathy ¾ç½Â¾Æ(°¡Å縯ÀÇ´ë Ç÷¾×Á¾¾ç³»°ú) ±³À°½Ã°£ 03¿ù 09ÀÏ ¿Â¶óÀÎ 11:40~12:10 Anemia in diabetic kidney disease ±Ç¼ÒÀÌ(Áß¾ÓÀÇ´ë ½ÅÀå³»°ú)
|
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|
Á¦¸ñ |
Ãßõ¼ö : 1 , Á¶È¸¼ö : 521 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 549 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 404 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 528 , ´ñ±Û¼ö : 1 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 6,062 , ´ñ±Û¼ö : 0 |